ViroMed Preps US Trial For First Diabetic Ulcer Gene Therapy
This article was originally published in PharmAsia News
After receiving US FDA approval to start a Phase III clinical trial with its gene therapy for diabetic peripheral neuropathy earlier this year, South Korea’s ViroMed is set for another Phase III study in the US, this time for a chronic non-healing ischemic diabetic foot ulcer therapy, which is the first gene therapy to be developed for this indication and which the firm is looking to partner.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.